Galactose and the role of circulating permeability factors in FSGS

A review of oral galactose, a sugar, which appears to provide hope in limited cases of treatment of FSGS 

MYH9 gene, the high rate of FSGS in African Americans explained

An exploration of the genetic discovery explaining the increased burden of kidney disease in African Americans       

Rituximab, a clinical update

Recent studies evaluate the use of rituximab in patients with steroid resistant and dependent NS and FSGS but studies continue to draw questions

Fibrosis and FSGS, a review of the FONT study

A new role for an old antidiabetic drug, rosiglitazone, as an antifibrotic medication in the treatment of steroid resistant FSGS

Exploring the growing numbers of FSGS nationally

Exploring the increase in biopsy proven primary FSGS and ESRD in the US

The financial burden and complications of nephrotic syndrome

It appears that the percentage of complications as well as the cost of treatment of NS in children is increasing nationally

Beyond immunosuppression, a new role for cyclosporine

Previously thought to function by suppressing the immune system, a discovery is made that Cyclosporine may have a more direct effect on the kidney

Long term outcome of nephrotic syndrome and FSGS in children

Questions remain regarding the long term outcome of these potentially devastating kidney diseases in children, a longitudinal review of two international kidney centers is provided